Insilico Drug Designing and Pharmacokinetics Studies on the Gene, Macc1 (Metastasis Associated Gene in Colon Cancer 1), Responsible for Colon Cancer

Globally more than 1 million people get colorectal cancer every year resulting in about 715,000 deaths as of 2010 up from 490,000 in 1990. As of 2012, it is the second most common cause of cancer in women (9.2% of diagnoses) and the third most common in men (10%). In this research, we focused on the potential mutated gene, MACC1 – Metastasis-Associated Gene in Colon Cancer 1. We examined the potential mutated sites which are responsible for colon cancer. We modeled the 3D structure of both the normal and the mutated protein and validated it. The potential existing drug and the anti-oxidant agent were combined using advanced cheminformatics protocols. The designed drug was validated using pharmacokinteics techniques (ADME and Toxicity). Finally the designed drug and the control drug were docked using automated drug docking server. Based on the drug binding scores, we deduced that the designed drug has good binding affinities with the target modeled protein. Hence, we finally conclude that the regions of MACC1 act as therapeutic agent for Colon cancer.